Oral cephalosporins in the ent-practice
https://doi.org/10.21518/2079-701X-2018-8-46-51
Abstract
The article presents modern data on antibacterial therapy for acute infectious and inflammatory diseases of the upper respiratory tract and ear, provides a overview of the most commonly used antibiotics in the practice of ENT, as well as clinical studies devoted to the study of the efficacy and safety of the drug Spectracef – a representative of the cephalosporin group.
About the Authors
S. V. Morozova
I.M. Sechenov First Moscow State Medical University
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
M. V. Svistushkin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Ain MR, Shahzad N, Aqil M, Alam MS, Khanam R. Drug utilization pattern of antibacterials used in ear, nose and throat outpatient and inpatient departments of a university hospital at New Delhi, India. Journal of Pharmacy and Bioallied Sciences, 2010, 2(1): 8-12. doi: 10.4103/0975-7406.62695.
2. Buchineni, Madhavulu & Pathapati, Rama & Srinivas, Golve & Kudagi, Babasaheb. (). Drug utilization study of antimicrobials in ent out patient department in a tertiary care hospital in south india. Asian academic research journal of multidisciplinary, 2014, 1: 426-432.
3. Kishore Kumar Y, Cheekavolu C, Obulesu G. Drug utilization pattern in ENT OPD of government tertiary care teaching hospital in Raigarh. International Journal of Otorhinolaryngology and Head and Neck Surgery, 2017 sep, 3(4): 1042-1045.
4. Vanitha M. Prescribing Pattern of Antibiotics in Patients Attending ENT OPD in A Tertiary Care Hospital. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 2017, 16.9: 30-33. doi: 10.9790/0853-1609023033.
5. Sathiya Sanket B. et al. Drug utilization pattern of antimicrobial agents in an outpatient department of otorhinolaryngology in a tertiary care hospital: a prospective, cross-sectional study. International Journal of Basic & Clinical Pharmacology, 2016 dec, 5(1): 65-69. doi. org/10.18203/2319-2003.ijbcp20160102
6. Kousalya K, Thirumurugu S, Arumainayagam DC, Manavalan R, Vasantha J, Reddy CUM. Antimicrobial resistance of bacterial agents of the upper respiratory tract in south indian population. Journal of Advanced Pharmaceutical Technology & Research, 2010, 1(2): 207-215.
7. Wang L, Qiao X, Ai L, Zhai J, Wang X. Isolation of antimicrobial resistant bacteria in upper respiratory tract infections of patients. 3 Biotech, 2016, 6(2): 166. doi: 10.1007/s13205-016-0473-z.
8. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic Advances in Drug Safety, 2014, 5(6): 229-241. doi: 10.1177/2042098614554919.
9. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiology spectrum, 2016, 4(2). doi: 10.1128/microbiolspec.VMBF-0016-2015.
10. Von Wintersdorff CJH, Penders J, van Niekerk JM, et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. Frontiers in Micro biology, 2016, 7: 173. doi: 10.3389/fmicb.2016.00173.
11. Belocerkovsky B.Z., Gelfand E.B. et al. The place and efficacy of cefoperazone/sulbactam in surgery and intensive care (a brief review of the literature and own observations). Consilium Medicum. Surgery infection, 2007, 5(2): 43-51.
12. García-Rodríguez JA, Muñoz Bellido JL, García Sánchez JE. Oral cephalosporins: current perspectives. International Journal of Antimicrobial Agents, 1995, 5(Issue 4): 231-243. https: //doi. org/10.1016/0924-8579(95)00015-Z.
13. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus infuenzae, Moraxella catarrhalis and Streptococcus-pneumoniae in the United States. Antimicrob Agents Chemother, 1990, 34: 2075-2080.
14. Lark RL & Chenoweth C. Antimicrobial resistance in community-acquired respiratory tract pathogens. Comprehensive Therapy, 1999, 25(1): 20. https: //doi.org/10.1007/BF02889831.
15. Coffey TJ, Dowson CG, Daniels M, Spratt BG. Genetics and molecular biology of β-lactamresis tant pneumococci. Microb. Drug. Resist, 1995, 1: 29–34.
16. Williams JD. Classification of cephalosporins. Drugs, 1987, 34(suppl 2): 15-22.
17. Thornsberry C. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis, 1992, 14: 189-194.
18. Doern G. In vitro activity of loracarbef, and effects of susceptibility test methods. Am J Med, 1992, 92(suppl 6A): 7-15.
19. Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixi-me, cefdinir, cefetamet, ceftibuten, oracarbef, cefprozil, BAY 3522.
20. Kozlov R.S., Dechnich A.V. Cefditoren of pivoxil: clinical, pharmacological and microbiological characteristics. CMAC, 2014, 16(2): 111-129.
21. Differential diagnosis and treatment of acute tonsillopharyngitis. Clinical recommendations. National medical Association of otolaryngologists, 2016: 12-14.
22. Principles of etiopathogenetic therapy of acute sinusitis. Clinical recommendations. National medical Association of otolaryngologists. 2016: 14-17.
23. Yamada M, Watanabe T, Miyara T et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother, 2007, 51: 45-50.
24. Asahi Y, Takeuchi Y, and Ubukata K.. Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother, 1999, 43: 1252–1255.
25. Purdue Pharmaceutical Products L.P. Package insert: Spectracef® tablets (cefditoren pivoxil) [online]. Available from URL: http: //www.pharma.com/PI/ Prescription/spectracef.pdf Accessed 2004 Aug 23.
26. Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren [poster no. 310]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 Sep 17-20, Toronto.
27. FDA Spetracef Patient Information Leaflet dated 08.06.2012.
28. Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter, 2009, 22: 57-61.
29. Drugs reestr. www.rls.net. Accessed at 23.02.18
30. Svistushkin V.M., Slavsky A.N., Pshonkina D.M. Bacteriophages in complex treatment of acute bacterial rhinosinusitis. RMJ, 2014, 26: 19-25.
Review
For citations:
Morozova SV, Svistushkin MV. Oral cephalosporins in the ent-practice. Meditsinskiy sovet = Medical Council. 2018;(8):46-51. (In Russ.) https://doi.org/10.21518/2079-701X-2018-8-46-51
Views:
1072
Email this article 